Abstract
Treatment of pediatric type 2 diabetes (T2D) is extremely challenging for many reasons. Chief among these are the fact that metformin had been the only drug approved for use in adolescents with T2D for more than 20 years based on the results of a randomized clinical trial. Insulin was approved for use in pediatric T2D, but this was extrapolated from its effectiveness in youth with T1D and in adults with T2D. During the past year, liraglutide (a GLP1 agonist) was also approved for use in youth with T2D. However, the liraglutide study required more than 4 years to complete, and similar challenges are being faced by other randomized clinical trials of new drugs that have been approved for use in adults with T2D. In addition to reviewing the benefits and limitations of currently approved drugs in youth with T2D, we explain some of the challenges faced in trying to complete these trials.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996;128:608–15.
Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002;25:89–94.
Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314:2241–50.
TODAY Study Group. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the pre-randomization run-in phase of the TODAY study. Pediatr Diabetes. 2012;13:369–73.
TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56.
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of switching youth with diabetes to insulin degludec in clinical practice. Endocr Pract. 2019;25:226–9.
Gregg B, Connor CG, Cheng P, et al. C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatr Diabetes. 2016;17:274–80.
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV. Youth with type 1 and type 2 diabetes in the Pediatric Diabetes Consortium (PDC) Registries: comparing clinical characteristics and glycemic control diabetes. Medicine. 2020;37:863–7.
Tamborlane WV, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch J, Rao PV, Shehadeh N, Turan S, Weghuber D, Barrientos-Pérez M, Barrett T. Liraglutide in children and adolescents with type 2 diabetes. NEJM. 2019;381:637–46.
Farrell R, Bethin K, Klingensmith G, Tamborlane WV, Gubitosi-Klug R. Barriers to participation in industry-sponsored clinical trials in pediatric type 2 diabetes. Pediatr Diabetes. 2017;18:574–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Samuels, S., Van Name, M., Guandalini, C., Tamborlane, W.V., Caprio, S. (2021). Current Treatment of Pediatric Type 2 Diabetes. In: Tamborlane, W.V. (eds) Diabetes in Children and Adolescents. Contemporary Endocrinology. Humana, Cham. https://doi.org/10.1007/978-3-030-64133-7_18
Download citation
DOI: https://doi.org/10.1007/978-3-030-64133-7_18
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-64132-0
Online ISBN: 978-3-030-64133-7
eBook Packages: MedicineMedicine (R0)